Induction of Labor in Women With Unfavorable Cervix: Randomized Control Study Comparing Dilapan to Foley Bulb
Overview
- Phase
- Not Applicable
- Intervention
- Not specified
- Conditions
- Pre-induction Dilation of Cervix
- Sponsor
- The University of Texas Medical Branch, Galveston
- Enrollment
- 419
- Locations
- 2
- Primary Endpoint
- Rate of Vaginal Delivery
- Status
- Completed
- Last Updated
- 5 years ago
Overview
Brief Summary
Women undergoing mechanical cervical ripening for labor induction will be randomized to Dilapan-S® versus Foley bulb. The investigators hypothesized that osmotic cervical dilators (Dilapan-S®) are as effective as Foley bulb catheter in rates of vaginal delivery.
Detailed Description
Historically, mechanical methods were the first methods developed to ripen the cervix or to induce labor. Dilapan-S® a synthetic osmotic cervical dilator made of a patented hydrogel (AQUACRYL), works by stimulating the release of endogenous prostaglandins, which degrade collagen fibers and soften the cervix. Additionally, it dilates the cervix gradually and the effect is gentle as well as predictable. Recently, Dilapan-S® has been approved by the FDA as a mechanical dilator for cervical ripening. There are no data comparing this newly approved Dilapan-S® to the Foley catheter, the most commonly used mechanical dilator method. Therefore, The investigators propose a randomized controlled trial to determine the efficacy of Dilapan-S® compared with Foley catheter for cervical ripening before induction of labor in pregnant women greater than 37 weeks.
Investigators
Eligibility Criteria
Inclusion Criteria
- •Pregnant woman scheduled for induction of labor.
- •Age between 18 and 45 years.
- •Understanding and capable to sign informed consent.
- •Singleton pregnancy.
- •Gestational age ≥ 37 0/7 weeks.
- •Live fetus in cephalic presentation.
- •Intact membranes.
- •Pelvic exam (sterile vaginal exam) of less than or equal to 3cm and at most 60% effaced.
Exclusion Criteria
- •Iodine allergy.
- •Active labor or oxytocin has been administered.
- •Chorioamnionitis.
- •Prior uterine or cervical surgery.
- •Non reassuring fetal status requiring immediate delivery.
- •Non-cephalic fetal presentation.
- •Active vaginal bleeding from cervical os.
- •Placenta previa.
- •EFW \> 5000 gm(non diabetic) or \> 4500gm (diabetic).
- •Other contraindication to vaginal delivery.
Outcomes
Primary Outcomes
Rate of Vaginal Delivery
Time Frame: Through study completion, an average of 1-2 years
Proportion of patients that delivered vaginal. (%)
Secondary Outcomes
- Time to Reach Active Stage of Labor as ≥ 6cm Cervical Dilation(1-2 days)
- Change in Bishop Scores(12-24 hrs)
- Operative Deliveries(1-4 days)
- Cesarean Deliveries(1-4 days)
- Time of Vaginal Delivery(2-4 days)